Lindsay Brust-Sisti

Dr. Lindsay Brust-Sisti


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
MSMarc Sturgill
Marc Sturgill
LVLucio R. Volino
Lucio R. Volino

27 October 2021 in Cureus
Verified
Journal Article
Open access
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
RSReema Shah
Reema Shah
GFGermin Fahim
Germin Fahim
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
The current state of the opioid epidemic has revealed the need of utilizing proper pain management, especially in the postoperative setting where there is overuse of potent analgesics. However, the adequate treatment of pain is necessary to reduce mortality and cost of burden while increasing recovery and improving quality of life. Treatment of pain can be difficult to standardize as the guidelines from the American Pain Society discuss the importance of tailoring treatment options based on a patient’s sensitivities and risk factors. An effective fast-acting analgesic with adequate potency and few adverse events is the key to alleviating acute pain. Oliceridine (Olinvyk®, Trevena Inc., Chesterbrook, USA) is a novel G protein-biased μ-opioid receptor agonist designed to decrease opioid-related adverse events (ORAEs) compared to conventional opioids. This article discusses oliceridine’s novel mechanism of action and current place in therapy. After a literature search on clinicaltrials.gov, three clinical trials were analyzed to understand the safety and efficacy of oliceridine. These trials demonstrated a comparable efficacy to morphine with a decreased risk for serious adverse events. However, further studies need to be conducted to evaluate the true safety impact of oliceridine compared to conventional opioids.

30 November 2022 in Pharmacy
Verified
Journal Article
Open access
PDF file
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
NRNicole Rudawsky
Nicole Rudawsky
JGJimmy Gonzalez
Jimmy Gonzalez
Luigi BrunettiLuigi Brunetti
Luigi Brunetti
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of antidiabetic mediations found to also reduce cardiovascular morbidity and mortality and hospitalization for heart failure. Positive results from the EMPEROR-Preserved (empagliflozin) and PRESERVED-HF (dapagliflozin) studies led to recommendations for SGLT2 inhibitors in HFpEF within major international heart failure guidelines. However, studies of ipragliflozin and luseogliflozin, agents approved outside the United States (U.S.), reported different outcomes relative to pivotal trials and failed to realize benefits in the HFpEF population. Varying definitions of HFpEF and outcomes studied complicate the interpretation of study results. SGLT2 inhibitors may cause common adverse events (genital mycotic infections, volume depletion) in addition to rare but severe sequela, including euglycemic diabetic ketoacidosis, Fournier’s gangrene, and lower limb amputation. While evidence of CV benefits grows, SGLT2 inhibitor prescribing has lagged, particularly among patients without diabetes. In the U.S., high cost and administrative hurdles may contribute to decreased patient and clinician uptake of this drug class. Future trial results and clinical experience with SGLT2 inhibitors may lead to expanded use and greater uptake among patients with heart failure.

31 March 2022 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
MAMark E. Armanious
Mark E. Armanious
KOKelly Ohlinger
Kelly Ohlinger
JPJainaben Patel
Jainaben Patel
TLTanvi Lodhia
Tanvi Lodhia
LVLucio R. Volino
Lucio R. Volino
Background Point of care testing (POCT) for Coronavirus Disease 2019 (COVID-19) is a major source of its control. On May 13, 2020, NJ pharmacists were authorized to order and perform COVID-19 testing, expanding their role in the response to the COVID-19 pandemic. Objective: The purpose of this study was to evaluate NJ pharmacists’ perceptions on the safety and potential consequences of performing COVID-19 testing within their community pharmacy practice sites. Methods: An electronic survey was distributed to NJ-registered pharmacists approximately 3 months after the administrative order was issued. Results: The survey was completed by 523 recipients (3.39% response rate) and responses from 311 NJ pharmacists practicing in community pharmacy were analyzed. The majority of respondents (83.8%) were not providing testing, while 16.2% were testing at the time of survey distribution. Most testing pharmacists were staff pharmacists with one to five years of experience, working in a pharmacy chain approximately 30-40 hours per week. Those not testing identified lack of a pharmacy drive-through, insufficient staff, and potential workflow disruption as reasons for not testing. Increased workload and fear of spreading the virus to others were concerns noted by both testers and non-testers. Conclusion: Overall, NJ pharmacists reported mixed perceptions regarding performing COVID-19 testing. Challenges and barriers to pharmacist COVID-19 testing, including inadequate staffing and space, and concerns about reimbursement and disruption to workflow were identified. Findings may serve as a guide to design and implement strategies to overcome barriers.

1 January 2023 in Substance Abuse: Research and Treatment
Verified
Journal Article
Open access
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
TKTiffany Khieu
Tiffany Khieu
SPSlava Plotkin
Slava Plotkin
MSMarc G Sturgill
Marc G Sturgill
SMSandy Moreau
Sandy Moreau
Background: Patients with substance use disorders are often encountered in an acute care setting and withdrawal management is important. Available literature reveals inadequate acute management of substance withdrawal due to lack of experience and knowledge of medications. Methods: A quality improvement project was implemented to improve hospital pharmacists’ knowledge, application, and practice of inpatient opioid and alcohol withdrawal management through provision of didactic and case-based education and implementation of practice based prospective drug utilization review (PDUR). Pharmacists’ knowledge of the management of alcohol and opioid withdrawal was assessed by a 10-item survey pre-and post-intervention. Results: Twenty-one pharmacists completed the education and pre- and post-surveys. Scores for the 21 pharmacists improved significantly, with pre- and post-intervention scores of 7.33 ± 1.98 and 8.86 ± 0.91, respectively ( P = .0035). Most pharmacists completed their required PDUR submission, and several pharmacist interventions were made and accepted post-education. Pharmacists indicated that the education increased their confidence and enabled them to learn new information that could be directly applied to their pharmacy practice. Conclusion: Providing education and requiring a PDUR improved pharmacists’ knowledge, application, and practice of inpatient opioid and alcohol withdrawal management. Re-education or expanded education may be warranted to further increase pharmacists’ competence.

27 July 2025 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
GHGwang-Yee Hu
Gwang-Yee Hu
MBMatthew Bridgeman
Matthew Bridgeman
Luigi BrunettiLuigi Brunetti
Luigi Brunetti
JGJimmy Gonzalez
Jimmy Gonzalez
Objective: To compare the efficacy and safety of ceftriaxone (CRO) 1 g intravenously (IV) daily to higher doses for treating non-central nervous system (CNS) infections in adults. Data Sources: PubMed, Embase, Scopus, and Web of Science were used. A search was run from database inception to August 8, 2023 and rerun May 12, 2025. Search terms were CRO, Rocephin, pneumonia, intra-abdominal infections, appendicitis, typhlitis, pyelonephritis, bacteremia, and sepsis. Study Selection and Data Extraction: Articles included had to compare CRO 1 g IV daily to higher dosing for the outcomes of interest: clinical cure (CC), hospital length of stay (LOS), mortality, and toxicity. Randomized controlled trials (RCTs) or observational studies were included. Studies including pediatric, pregnant, and outpatient administration were excluded. Clinical cure was evaluated using a Mantel-Haenszel random-effects model with Peto odds ratios (pORs), and 95% confidence intervals (CIs) were calculated. Heterogeneity was identified using Cochrane I 2 statistic. Data Synthesis: Eight studies (5145 patients) were included. No statistically significant difference was found for CC (pOR 0.958; 95% CI [0.525-1.749]; I 2 = 60.23; P = .888); LOS (Std difference in means, 0.052; 95% CI [−0.418, 0.523]; I 2 = 96.047; P = .828); or mortality (pOR 0.932; 95% CI [0.789-1.100]; I 2 = 0.000; P = .405). Relevance to Patient Care and Clinical Practice: Ceftriaxone dosing ranges from 1 to 2 g IV daily for treating non-CNS infections. Optimal dosing remains controversial, as RCTs have used different doses. This meta-analysis showed no difference between high and low CRO dosing for efficacy and safety. Because infection type and pharmacokinetic factors were not accounted for, findings may not be applicable to certain high-risk infections or situations where CRO pharmacokinetics are altered, such as hypoalbuminemia. Prospective studies can compare regimens and confirm findings. Conclusions: Ceftriaxone doses greater than 1 g IV daily did not improve CC, LOS, or mortality.